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Cationic arene ruthenium complexes that are air-stable and
water-soluble are ﬁnding increasing interest in many areas [1]
including homogeneous catalysts [2], polymeric materials [3],
nanocages [4] and nanoparticle precursors [5]. Notably, arene
ruthenium compounds are also being explored for their medicinal
properties as anticancer agents [6]. Arene ruthenium complexes of
the type (g6-arene)RuCl2(imidazole) [7] (g6-arene)RuCl2(PTA)
(PTA = 1,3,5-triaza-7-phosphaadamantane) [8], [(g6-arene)Ru-
Cl(en)]+ (en = ethylenediamine) [9], (g6-arene)RuCl2(DMSO) [10],
have been studied for their antitumour activity in vitro and in some
cases in vivo. The ethylenediamine series of complexes have been
evaluated for activity both in vitro and in vivo against human ovar-
ian cancer, which show high activity coupled to non cross-resis-
tance in cisplatin resistant models [11]. The PTA series of
compounds were found to effectively reduce the growth of lung
metastases in CBA mice bearing the MCa mammary carcinoma
[12]. Other anticancer compounds based on the arene ruthenium
unit include those with modiﬁed paullone ligands [13] and ferro-
cene moieties [14] and bridging systems [15]. The arene rutheniumFink).unit has even been attached via a pH cleavable linker to human
serum albumin as a drug delivery vector [16].
Recently, we reported the synthesis of tris–thiolato-bridged
complexes of the type [(g6-arene)2Ru2(l-SR)3]+ (arene = C6H6,
p-iPrC6H4Me, C6Me6; R = p-C6H4Me, CH2CH2OH, p-C6H4OH), acces-
sible from the reaction of (g6-arene)2Ru2(l2-Cl)2Cl2 with the corre-
sponding thiol [17] (Scheme 1). In contrast, the mono and
dithiolato-bridged complexes [(g6-arene)2Ru2(l-H)2(l-SR)]+ and
[(g6-arene)2Ru2(l-H)(l-SR)2]+ (arene = p-C6H2Me4, C6Me6; R = p-
C6H4Me, p-C6H4Br) may be obtained from [(g6-arene)2Ru2(l-
H)3]+ by reaction with the corresponding thiophenol [18].
Using a similar approach, (g6-arene)2Ru2(l2-Cl)2Cl2 was re-
acted with 4-pyridinethiol (4-mercaptopyridine), in order to syn-
thesise tris–thiolato-bridged complexes analogous to those
depicted in Scheme 1. Surprisingly, the reaction proceeds in a dif-
ferent way and gives rise to the formation of mononuclear cations,
involving the rearrangement of three pyridinethiol molecules to
pyridinium–thiolato ligands. In addition, the isomeric 2-pyridi-
nethiol (2-mercaptopyridine) reacts with (g6-C6Me6)2Ru2(l2-
Cl)2Cl2 in a different manner, leading to neutral mononuclear thio-
lato complexes. Furthermore, since pyridinium–thiolato ligands
combined with platinum demonstrate excellent anticancer activity
[19], we decided to explore the in vitro cytotoxicity of these com-
pounds and to establish whether their activity correlates with their
biologically accessible redox potential.
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22. Results and discussion
2.1. Syntheses and characterisation of 1–4
The dinuclear arene ruthenium complexes (g6-arene)2Ru2(l2
Cl)2Cl2 (arene = C6H6, C6H5Me, p-iPrC6H4Me, C6Me6) react with 4
pyridinethiol (4-mercaptopyridine) in reﬂuxing ethanol to giv
the mononuclear ruthenium complexes [(g6-arene
Ru(SC5H4NH)3]2+ (1–4), the yields being higher if technical grad
ethanol (5.6% water) is used. The reaction formally involves th
transfer of the hydrogen atom in 4-pyridinethiol from sulphur t
nitrogen to form a 4-pyridinium–thiolato ligand (Scheme 2).
Complexes 1–4 are isolated as the chloride salts which are ye
low to red air-stable crystalline solids. They are soluble in wate
methanol, ethanol, dimethylsulfoxide and acetonitrile, but not so
uble in dichloromethane, chloroform, tetrahydrofuran or hydroca
bon solvents. The 1H NMR spectra of 1–4 in DMSO-d6 show a broa
singlet for the pyridinium protons at d = 14.20 ppm for
14.05 ppm for 2, 13.76 ppm for 3 and 13.99 ppm for 4, which inte
grates to three N–H hydrogen atoms with respect to the other C–
signals.
In order to obtain X-ray quality crystals, the hexaﬂuorophos
phate salt of 4 was prepared by anion exchange of [4]Cl2 wit
KPF6 in wet methanol. The compound [4](PF6)2 crystallises from
this water–methanol solution in the form of orange needles. Th
molecular structure of cation 4 shows the ruthenium atom t
adopt a piano-stool geometry with the metal centre coordinate
by the arene ligand and the three sulphur atoms of the three 4
pyridinium–thiolato ligands. An ORTEP drawing with the atomRu
Cl
Ru
Cl Cl
Cl
R'
R'
R'
NHS
Schelabelling scheme for complex 4 is shown in Fig. 1 together with se
lected bond lengths and angles.
The Ru–S bond distances ranging from 2.3785(9) to 2.3923(9)
in 4 are comparable to those observed in [(g5-C5H5)Ru(PPh3
(NO)(SC5H4NH)]BF4 [20] and [(g5-C5H5)Ru(PPh3)(CO)(SC5H4N
[20]. Interestingly, to minimise steric repulsion between the thre
4-pyridinium–thiolato ligands, two S–Ru–S angles are quite obtus
[94.43(3) and 97.14(3)] while the remaining S–Ru–S angle is ex
tremely acute [80.69(3)]. Moreover, two pyridinium rings poin
away from each other, while the third pyridinium aromatic rin
is directed under the (g6-C6Me6)Ru moiety. The S–C bond dis
tances ranging from 1.712(4) to 1.719(4) Å in 4, as well as th
lengths of the C–C bonds ranging from 1.353(6) to 1.420(5) Å i
the pyridinium ring are in accordance with the ligands being aro
matic thiolato ligands rather than thione ligands.
The crystal of [4](PF6)2 contains four water molecules aroun
the dication and all the pyridinium moieties form a strong hydro
gen bond with water molecules (Fig. 2): the N  O distances bein
N(1)  O(1) 2.798(5), N(2)  O(2) 2.738(5) and N(3)  O(1
2.790(4) Å (i = x, 1 + y, z), respectively, with N–H  O angles o
N(1)–H  O(1) 163(5), N(2)–H  O(2) 164(4) and N(3)–H  O(1
175(5). In addition, one PF6 anion resides above the g6-aren
ligand with P–F  C distances ranging from 3.107(5) to 3.855(5) Å
2.2. Electrochemistry of 1–4
The redox behaviour of complexes 1–4 has been studied by cyc
lic voltammetry in the anodic region at a platinum disc electrode i
ca. 0.5 mM aqueous solutions of the complexes containing 0.1 M=
1 32 4
Ru
SS
R'
S
2+
N
N
N
H
H
H
me 2.
Fig. 1. ORTEP diagram of complex 4 with 50% probability thermal ellipsoids.
Hydrogen atoms, water molecules and PF6 anions are omitted for clarity. Selected
bond lengths (Å) and angles (): Ru(1)–S(1) 2.3923(9), Ru(1)–S(2) 2.3785(9), Ru(1)–
S(3) 2.3843(9), S(1)–C(13) 1.712(4), S(2)–C(18) 1.719(4), S(3)–C(23) 1.714(3); S(1)–
Ru(1)–S(2) 94.43(3), S(2)–Ru(1)–S(3) 97.14(3), S(1)–Ru(1)–S(3) 80.69(3).
Fig. 2. Pyridinium  OH2 hydrogen bonds observed in [4](PF6)2  4H2O.
Table 1
Summary of the electrochemical dataa
Compound Epa (V)
1 +0.67b
2 +0.65, ca. +0.81
3 +0.63, ca. +0.84
4 +0.58, +0.78
a Potentials are given relative to saturated calomel electrode. Epa is the anodic
peak potential.
b The wave due to second oxidation is not observed.
3NaClO4 as the supporting electrolyte. The pertinent data are sum-
marised in Table 1. Generally, the complexes undergo two consec-
utive irreversible oxidations (the second wave is hardly detectable
in the case of 1). The redox response is markedly obscured by
adsorption phenomena that result in extensive blocking of the
electrode surface1 and also make the determination of the redox po-
tential somewhat less accurate. Nevertheless, an inspection of the
data allows the ﬁrst wave to be assigned to an irreversible RuII?
RuIII oxidation as observed in the case of [(g6-arene)RuCl2(NC5H4-
OOCC5H4FeC5H5)] complexes, where the alkyl substituents at the
arene ligand have the same inﬂuence on the RuII/RuIII redox poten-
tials [14]. In the series, the associated redox potential decreases
linearly (by 100 mV over the series) with increasing the number of
alkyl the groups attached to the g6-arene ring, thus reﬂecting a1 No response is observed after the ﬁrst cycle, indicating full coverage of the
electrode surface.stronger electron-donating character that apparently makes the
electron removal easier (Fig. 3).
With values between +0.58 and +0.67 V, the RuII/RuIII redox
potentials for 1–4 are signiﬁcantly lower than those for the more
cytotoxic complexes [(g6-arene)RuCl2(NC5H4OOCC5H4FeC5H5)],
the Epa values ranging from +0.91 to +1.00 V [14]. However, as
for most arene ruthenium complexes with anti-cancer properties
electrochemical data are missing, a clear correlation between Epa
values and IC50 values cannot be claimed so far.
2.3. Anticancer activity of 1–4
The in vitro cytotoxicity of 1–4 was evaluated by the biological
MTT assay (see Section 3) which measures mitochondrial dehydro-
genase activity as an indication of cell viability using the A2780
ovarian cancer cell line. The compounds were incubated at various
concentrations (in triplicate) in the A2780 cells and cell viability
measured after an incubation period of 72 h. Each experiment
was conducted in duplicate and the IC50 values listed in Table 2
were calculated as an average over the two experiments.
There is no clear correlation between the IC50 values and the Epa
data, since the benzene derivative 1 is more cytotoxic than the al-
kyl-substituted arene derivatives 2–4, the latter ones correlating
well with the electrochemical data. For ruthenium compounds
the ‘activation by reduction’ mechanism, beside transferrin medi-
ated uptake, has been proposed to account for the low general tox-
icity of Ru(III) compounds [21]. Nevertheless, there is convincing
evidence to suggest that some metal-based anticancer drugs exert
their cytotoxic effect via other redox processes [22]. It should be
noted that the observed IC50 values are considerably higher than
those characteristic of cisplatin and other platinum agents, never-
theless a number of ruthenium-based compounds have been foundFig. 3. Correlation between the redox potential of the ﬁrst oxidation and the
number of alkyl groups (n) at the arene ring (the least-squares linear ﬁt is indicated
with a dashed line).
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Table 2
IC50 values of compounds 1–4 in the A2780 ovarian cancer cell line
Compound IC50 (lM)
1 148
2 294
3 195
4 74
4to show very good in vivo activity while displaying only a low
in vitro cytotoxicity [12,23].
2.4. Syntheses and characterisation of 5 and 6
For comparison, (g6-C6Me6)2Ru2(l2-Cl)2Cl2 was reacted with 2
pyridinethiol, the structural isomer of 4-pyridinethiol. The reactio
does not lead to a cationic pyridinium–thiolato complex, but in
stead to the neutral complex, (g6-C6Me6)Ru(g2-SC5H4N)(g1
SC5H4N) (5) (Scheme 3). Complex 5 is a yellow air-stable powde
soluble in dichloromethane, chloroform, acetone, DMSO and aceto
nitrile and is insoluble in methanol, ethanol and hydrocarbons. Th
1H NMR spectrum of 5 in DMSO-d6 shows a singlet at d = 2.03 ppm
for hexamethylbenzene hydrogen atoms and the expected signa
for the two heteroaromatic rings [d = 6.47 ppm (d), 6.60 ppm (d
6.61 ppm (d), 7.04 ppm (m), 7.22 ppm (dd), 8.06 ppm (d) an
8.13 ppm (d)]. The ESI mass spectrum of 5 displays a peak at m
374.20 corresponding to the fragment ion [(g6-C6Me6)Ru(g2
SC5H4N)H]+, but does not show the molecular peak. However, th
molecular constitution of 5 is conﬁrmed by the correct element
analysis.
In a similar way, (g6-C6Me6)2Ru2(l2-Cl)2Cl2 reacts with th
analogous 2-quinolinethiol in reﬂuxing ethanol to give (g6
C6Me6)Ru(g2-SC9H6N)(g1-SC9H6N) (6) in 66% yield (Scheme 3
Complex 6 is a red air-stable solid with solubility properties simila
to 5. The 1H NMR spectrum of 6 in DMSO-d6 exhibits a singlet a
d = 2.13 ppm for hexamethylbenzene hydrogen atoms togethe
with signals for the two heteroaromatic rings [d = 6.63 ppm (d
7.19 ppm (m), 7.30 ppm (m), 7.55 ppm (m), 7.78 ppm (d) an
8.03 ppm (d)]. The ESI mass spectrum of 6 contains a peak at m
424.30 corresponding to the fragment [(g6-C6Me6)Ru(g2
SC9H6N)H]+, in keeping with the spectrum of 5, with element
analysis conﬁrming the assignment. Since 5 and 6 are insolub
in water, their cytotoxicities were not assessed.
3. Experimental
3.1. General remarks
All reagents were purchased either from Aldrich or Fluka an
used as received. The complexes (g6-arene)2Ru2(l2-Cl)2Cl2 wer
prepared according to the literature methods [24]. NMR spectr
were recorded on a Bruker AMX 400 spectrometer using the residRu
Ru
Cl Cl
Cl
N
HS
Ru
S
S N
N
5
Scheual proton resonance of the deuterated solvent as internal stan
dard. Elemental analyses were performed by the Laboratory o
Pharmaceutical Chemistry, University of Geneva (Switzerland) o
by the Mikroelementaranalytisches Laboratorium, ETH Züric
(Switzerland). Electrospray mass spectra were performed by th
Department of Chemistry of the University of Fribourg (Switze
land). Electrochemical measurements were performed with a com
puter-controlled multipurpose polarograph AUTOLAB III (Ec
Chemie, Netherlands) at room temperature using a standard Met
ohm three-electrode cell with platinum disc electrode (AUTOLA
RDE; 3 mm diameter) as the working electrode, platinum shee
auxiliary electrode, and saturated calomel electrode as the refe
ence. The analysed compounds were dissolved in water (deionise
and subsequently distilled under argon) to give a solution contain
ing 5  104 M of the analyte and 0.1 M NaClO4 (Merck, p.a.). Th
solutions were degassed with argon prior to the measuremen
and then kept under an argon blanket. The redox potentials wer
reproducible within ca ±10 mV.
3.2. Synthesis
3.2.1. Synthesis of complexes 1–4
The complex (g6-arene)2Ru2(l2-Cl)2Cl2 (0.20 mmol, 100 mg fo
1, 105 mg for 2, 128 mg for 3, 133 mg for 4) was reﬂuxed in 50 m
of N2-saturated technical grade ethanol. When the complex ha
completely dissolved, a solution of 4-mercaptopyridine (133 m
1.20 mmol) in technical ethanol (5 mL) was added drop-wise t
the hot solution. The resulting mixture was reﬂuxed for 16 h. Afte
cooling to room temperature, the red solution was ﬁltered throug
celite in order to remove degradation products, and then the so
vent was removed under reduced pressure. The residue was dis
solved in methanol (5 mL), and the product was precipitated b
addition of diethyl ether (50 mL), isolated by ﬁltration and drie
in vacuo.
3.2.1.1. Spectroscopic data for [(g6-C6H6)Ru(SC5H4NH)3]Cl2 (catio
1). Dark-yellow solid, yield 200 mg (86%). 1H NMR (400 MH
DMSO-d6): 6.13 (s, 6H, C6H6), 7.58 (d, 3J = 7.2 Hz, 6H, H–Ar), 7.9
(d, 3J = 7.2 Hz, 6H, H–Ar), 14.20 (s, 3H, NH). 13C{1H} NM
(100 MHz, DMSO-d6): 89.77 (C6H6), 126.57 (CAr), 135.65 (CAr
179.07 (S–C). MS (ESI, m/z): 401 [MSC5H4NH]+, 29
[M2(SC5H4NH)]+. Anal. Calc. for C21H21Cl2N3RuS3  H2O: C
41.93; H, 3.85; N, 6.98. Found: C, 42.26; H, 3.92; N, 6.77%.
3.2.1.2. Spectroscopic data for [(g6-MeC6H5)Ru(SC5H4NH)3]Cl2 (catio
2). Dark-yellow solid, yield 197 mg (81%). 1H NMR (400 MH
DMSO-d6): 2.18 (s, 3H, CH3), 5.97 (d, 3J = 6 Hz, 2H, H–Ar), 6.0
(m, 3H, H–Ar), 7.63 (d, 3J = 6.8 Hz, 6H, H–Ar), 7.98 (d, 3J = 6.8 H
6H, H–Ar), 14.05 (s, 3H, NH). 13C{1H} NMR (100 MHz, DMSO-d6
18.34 (CH3), 85.47 (CAr), 87.07 (CAr), 91.77 (CAr), 107.8
(C–CH3), 126.69 (CAr), 135.45 (CAr), 178.91 (S–C). MS (ESI, m/z
415 [MSC5H4NH]+, 304 [M2(SC5H4NH)]+. Anal. Calc. foCl Ru SS
N
N
HS
N
6
me 3.
Table 3
Crystallographic and structure reﬁnement parameters for complex 4
[4](PF6)2  4H2O
Chemical formula C27H41F12N3O4P2RuS3
Formula weight 958.82
Crystal system Triclinic
Space group P1 (no. 2)
Crystal colour and shape Orange block
Crystal size (mm) 0.12  0.09  0.08
a (Å) 8.1214(6)
b (Å) 15.2254(12)
c (Å) 17.0575(13)
a () 67.194(6)
b () 79.343(6)
c () 88.307(6)
V (Å3) 1908.7(3)
Z 2
T (K) 203(2)
Dc (g cm3) 1.668
l (mm1) 0.754
Scan range () 1.32 < h < 25.66
Unique reﬂections 7201
Observed reﬂections [I > 2r(I)] 5463
Rint 0.0521
Final R indices [I > 2r(I)]a R1 0.0387, wR2 0.0928
R indices (all data) R1 0.0544, wR2 0.0964
Goodness-of-ﬁt 0.938
Max, Min Dq (eÅ3) 1.025, 0.665
a Structures were reﬁned on F20 : wR2 ¼ ½
P½wðF20  F2c Þ2=P
wðF20Þ21=2; where w1 ¼ ½
PðF20Þ þ ðaPÞ2 þ bP and P ¼ ½maxðF20 ;0Þ þ 2F2c =3.
5C21H21Cl2N3RuS3  H2O: C, 42.92; H, 4.09; N, 6.83. Found: C, 42.77;
H, 4.08; N, 6.71%.
3.2.1.3. Spectroscopic data for [(g6-p-iPrC6H4Me)Ru(SC5H4NH)3]Cl2
(cation 3). Orange solid, yield 236 mg (92%). 1H NMR (400 MHz,
DMSO-d6): 1.21 (d, 3J = 6.8 Hz, 6H, (CH3)2CH), 2.19 (s, 3H, CH3),
2.77 (sept, 3J = 7.2 Hz, 1H, (CH3)2CH), 5.79 (m, 4H, H–Ar), 7.7 (d,
3J = 7 Hz, 6H, H–Ar), 7.88 (d, 3J = 7 Hz, 6H, H–Ar), 13.76 (s, 3H,
NH). 13C {1H} NMR (100 MHz, DMSO-d6): 17.38 ((CH3)2CH), 22.01
(CH3), 30.02 ((CH3)2CH), 86.88 (CAr), 89.54 (CAr), 106.21 (CAr),
108.24 (CAr), 126.76 (CAr), 135.22 (CAr), 178.46 (S-C). MS (ESI,
m/z): 457 [MSC5H4NH]+, 346.1 [M2SC5H4NH]+. Anal. Calc. for
C25H29Cl2N3RuS3  2H2O: C, 44.44; H, 4.92; N, 6.22. Found: C,
44.63; H, 4.66; N, 6.21%.
3.2.1.4. Spectroscopic data for [(g6-C6Me6)Ru(SC5H4NH)3]Cl2 (cation
4). Red solid, yield 250 mg (94%). 1H NMR (400 MHz, DMSO-d6):
1.98 (s, 18H, CH3), 7.57 (d, 3J = 8 Hz, 6H, H–Ar), 7.85 (d, 3J = 8 Hz,
6H, H–Ar), 13.99 (s, 3H, NH). 13C{1H} NMR (100 MHz, DMSO-d6):
14.81 (CH3), 98.28 (CAr), 126.49 (CAr), 134.83 (CAr), 178.1 (S–C).
MS (ESI, m/z): 485.1 [MSC5H4NH]+, 374.1 [M2SC5H4NH]+. Anal.
Calc. for C27H33Cl2N3RuS3  H2O: C, 47.29; H, 5.14; N, 6.13. Found:
C, 47.39; H, 5.34; N, 5.75%.
3.2.2. Synthesis of complexes 5 and 6
The complex (g6-C6Me6)2Ru2(l2-Cl)2Cl2 (100 mg, 0.15 mmol)
was reﬂuxed in N2-saturated technical grade ethanol (50 mL).
When the complex had completely dissolved, a solution of 2-mer-
captopyridine (100 mg, 0.9 mmol) or 2-quinolinethiol (145 mg,
0.9 mmol) in technical ethanol (5 mL) was added drop-wise to
the hot solution. Then the resulting mixture was reﬂuxed for an-
other 16 h. After cooling to room temperature, the solution was ﬁl-
tered through celite in order to remove degradation products, and
then the solvent was removed under reduced pressure. In the case
of 5, the residue was dissolved in methanol (5 mL), and the product
was precipitated by addition of diethyl ether (50 mL), isolated by
ﬁltration and dried in vacuo. Compound 6 was puriﬁed by column
chromatography (aluminium oxide, CH2Cl2/acetone 1:1, Rf  0.8)
and was isolated by evaporation of the solvent and dried in vacuo.
3.2.2.1. Spectroscopic data for (g6-C6Me6)Ru(g2-SC5H4N)(g1-SC5H4N)
(5). Orange solid, yield 88 mg (61%). 1H NMR (400 MHz, DMSO-
d6): 2.03 (s, 18H, CH3), 6.47 (d, 3J = 8 Hz, 1H, CH), 6.61 (dd, 2H,
CH), 7.04 (m, 2H, CH), 7.22 (dd, 3J = 8 Hz, 1H, CH), 8.06 (d, 1H,
CH), 8.13 (d, 3J = 8 Hz, 1H, CH). 13C{1H} NMR (100 MHz, DMSO-
d6): 15.62 (CH3), 93.14 (CMe), 115.18, 115.37 (CH), 128.19, 133
(CH), 128.89 (CH), 134.25 (CH), 147.57 (CH), 148.99 (CH), 134.83
(CH), 171.19, 177.64 (S–C). MS (ESI, m/z): 506.9 [M+Na]+, 484.9
[M+H]+, 374.2 [M(SC5H4N)+H]+. Anal. Calc. for C22H26N2RuS2: C,
54.63; H, 5.42; N, 5.79. Found: C, 54.60; H, 5.44; N, 5.70%.
3.2.2.2. Spectroscopic data for (g6-C6Me6)Ru(g2-SC9H6N)(g1-SC9H6N)
(6). Red solid, yield 115 mg (66%). 1H NMR (400 MHz, DMSO-d6):
2.13 (s, 18H, CH3), 6.63 (d, 1H, CH), 7.19 (m, 2H, CH), 7.30 (m,
2H, CH), 7.55 (m, 5H, CH), 7.78 (d, 1H, CH), 8.03 (d, 1H, CH).
13C{1H} NMR (100 MHz, DMSO-d6): 16.34 (CH3), 93.72 (CMe),
121.84 (CH), 125.53 (CH), 127.84 (CH), 128.61 (CH), 129.88 (CH),
131.42 (CH) 132.11 (CH), 132.53 (CH), 133.64 (CH), 176.32 (S–C).
MS (ESI, m/z): 584.9 [M+H]+, 424.3 [M(SC5H4N)+H]+. Anal. Calc.
for C30H30N2RuS2: C, 61.72; H, 5.18; N, 4.80. Found: C, 61.68; H,
5.25; N, 4.74%.
3.3. Single crystal X-ray structure analysis
A crystal of [4](PF6)2  4H2O was mounted on a Stoe Image Plate
Diffraction system equipped with a / circle goniometer, using MoKa graphite monochromated radiation (k = 0.71073 Å) with /
range 0–200. The structure was solved by direct methods using
the program SHELXS-97 [25]. Reﬁnement and all further calculations
were carried out using SHELXL-97 [26]. The H-atoms were found on
Fourier difference map or included in calculated positions and trea-
ted as riding atoms using the SHELXL default parameters. The non-H
atoms were reﬁned anisotropically, using weighted full-matrix
least-square on F2. Crystallographic details are summarised in Ta-
ble 3. Fig. 1 was drawn with ORTEP [27] and Fig. 2 with the soft-
ware MERCURY [28].3.4. Cytotoxicity study
The human A2780 ovarian cancer cell line was obtained from
the European Collection of Cell Cultures (Salisbury, UK). Cells were
grown routinely in RPMI medium containing glucose, 5% foetal calf
serum (FCS) and antibiotics at 37 C and 5% CO2. Cytotoxicity was
determined using the MTT assay (MTT = 3-(4,5-dimethyl-2-thia-
zolyl)-2,5-diphenyl-2H-tetrazolium bromide). Cells were seeded
in 96-well plates as monolayers with 100 lL of cell solution
(approximately 20000 cells) per well and preincubated for 24 h
in medium supplemented with 10% FCS. Compounds were dis-
solved directly in the culture medium and serially diluted to the
appropriate concentration. 100 lL of drug solution was added to
each well and the plates were incubated for another 72 h. Subse-
quently, MTT (5 mg/mL solution) was added to the cells and the
plates were incubated for a further 2 h. The culture medium was
aspirated, and the purple formazan crystals formed by the mito-
chondrial dehydrogenase activity of vital cells were dissolved in
DMSO. The optical density, directly proportional to the number
of surviving cells, was quantiﬁed at 540 nm using a multiwell plate
reader and the fraction of surviving cells was calculated from the
absorbance of untreated control cells. Evaluation is based on
means from two independent experiments, each comprising three
microcultures per concentration level.
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6Supplementary material
CCDC 687524 contains the supplementary crystallographic dat
for this complex [4](PF6)2  4H2O. These data can be obtained fre
of charge from The Cambridge Crystallographic Data Centre v
www.ccdc.cam.ac.uk/data_request/cif.
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